Fritextsökning
Innehållstyper
-
He takes over the chairmanship of Karolinska Development
Ben Toogood is appointed as the new chairman of Karolinska Developments.
-
The US is leaving the WHO
The newly installed US President, Donald Trump, has issued an executive order for the US to leave the World Health Organization, WHO.
-
Wusson Accelerator AB
-
LINK Medical Research
-
NorthX Biologics Matfors AB
-
Small robots to deliver pharmaceuticals to the body
Robots that can operate inside the body and a platform that combines ultrasound with AI. These are a couple of the technologies that have qualified for a list t...
-
Marie Gårdmark: Finally, it’s time for a revision of the EU pharma legislation
A challenge for the EU Commission is to deliver a new framework that will also take care of another “pillar” of the pharmaceutical strategy, namely, to ensure that new medicines will be available for all citizens in Europe, writes Marie Gårdmark...
-
Uncertainty about the government’s life science work
The government’s national coordinator for life science, Jenni Nordborg, left her position almost four months ago. No one has yet succeeded her, and now question...
-
Lillys GLP-1-tablett nådde målen i typ 2-diabetesstudie
Läkemedelsbolaget Eli Lilly meddelar positiva resultat för GLP-1-tabletten orforglipron i två fas III-studier med typ 2-diabetespatienter.
-
Björn Ursing: Physicians new role in AI driven healthcare
”AI could be the key we need for tomorrow’s healthcare, but it is not a stand-alone tool”, writes Björn Ursing in a column about how the role for physicians cha...
-
Tio life science-projekt får miljonanslag – ny utlysning öppnar
En rad life science-projekt har fått miljonanslag i ett svenskt proof of concept-program. 13 januari öppnar en ny utlysning.
-
“What is important is to create an overview and understanding from different perspectives”
Scientist Jochen Schwenk analyses blood proteins using proteomics to improve our understanding of disease and health. This year, he is moderating the Lab & Diag...
-
Marie Gårdmark: New incentives for orphan products on its way
"Let’s hope that the learnings from development of new therapies for rare diseases will spill over to more common conditions, orphan products paving the wave fo...
-
Meribel Pharma Solna
-
Kvinnohälsojätte sparkar vd:n efter misstänkt försäljningsfiffel
Amerikanska Organon skakas av en skandal, där vd:n fått gå efter misstankar om tvivelaktiga försäljningsmetoder.
-
AI-företag köper tillgång till vetenskapliga studier – ”Svårt att reagera som forskare”
Stora förlag för vetenskapliga tidskrifter har i miljonaffärer sålt tillgång till studier till techbolag som utvecklar AI-verktyg. Reaktionerna bland svenska fo...
-
Pfizer värvar FDA-topp – kritiseras hårt
Läkemedelsjätten Pfizers rekrytering av Patrizia Cavazzoni, tills helt nyligen toppchef vid FDA, som ny medicinsk chef får frän kritik från flera håll.
-
In search of Marcel Proust's lost health
A great writer, but also a weak person and a hypochondriac. That has been the usual image of Marcel Proust. But the pediatrician and literary scholar Carl Lindg...
-
New rules for diagnostic products, but who will certify them? “An extreme shortage area”
In less than two weeks, new and stricter EU rules will enter into force for thousands of products used in important diagnoses of, among other things, cancer and...
-
New report: Fewer PhDs in life sciences
A new report from Vinnova suggests that competency returns in the life science sector are declining.
-
Mavatar AB
-
Faster development of reliable sample handling
Festo USA has collaborated with PerkinElmer to develop a compact sample handling solution for a global leader in manufacturing medical devices. Thanks to the cu...
-
Here are the pharmaceutical companies best prepared for AI
How well prepared are pharmaceutical companies in the field of artificial intelligence? That is what a new analysis has tried to evaluate.
-
Webinar: Medtech quality and regulatory compliance
This webinar is for you who are developing or planning to develop a medical device, combination, or borderline product. In one hour, we will discuss what you ne...